Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Although much work has focused on the elucidation of somatic alterations that drive the
development of acute leukaemias and other haematopoietic diseases, it has become …

Biallelic mutations of the CEBPA gene (CEBPA bi) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm) is poorly …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the proliferation and aberrant differentiation of immature clonal myeloid cells. The …

Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute
myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most …

We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures
of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA dm) versus …

Updating the classification of hematologic neoplasia with germline predisposition, pediatric
myelodysplastic syndrome (MDS), and juvenile myelomonocytic leukemia (JMML) is critical …

In-depth molecular investigation of familial leukemia has been limited by the rarity of
recognized cases. This study examines the genetic events initiating leukemia and details the …

Purpose To determine the clinical relevance of mutations in the CCAAT/enhancer binding
protein α (CEBPA) gene in acute myeloid leukemia (AML) and to examine factors that might …

Purpose CEBPA mutations are found as either biallelic (bi CEBPA) or monoallelic (mo
CEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic …